Stock Evaluator: Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals, Inc. ETON

$58.86 18.06 44.26%
August 14, 2026 4:00:00 PM EST November 10, 2021 Volume: 2,306,278
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Commentary & Analysis


Financial Summary

Share Statistics ETON Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,682.4 $587.7 51%
Shares Out (Mil) 32.8 44.5 38%
Institutional Ownership 90.5% 84.6% 59%
Float (Mil) 21.0 46.8 30%
Beta 0.87 0.69 52%
Avg Daily Volume (000s) 642 361 61%
Price Change
(52-week)
243.8% 66.7% 98%
Growth ETON Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) 30.3% (1.4%) 85%
EPS (5yr) 33.7% 14.9% 84
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (1.4%) (14.9%) 63%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS $0.190 $1.400 $2.580
Month Ago EPS $0.190 $1.010 $1.880
# Rev Up 0 1 1
# Rev Down 1 2 1
Three Months Ago EPS $0.190 $1.010 $1.880
Year/Year Chg (45.7%) (918.7%) (2,036%)
Financials ETON Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $106 $276 27%
Net Income (TTM) (Mil) $13 ($11) 47%
EPS (TTM) $0.467 ($0.700) 53%
Operating Cash Flow (TTM) (Mil) $15 ($6) 40%
Net Cash Flow (TTM) (Mil) $2 $5 47%
Long-Term Debt (Q1) (Mil) $20 $6 33%
Enterprise Value (Q1) (Mil) $1,169 $309 44%
Valuation ETON Industry
Median
Percentile
(All Stocks)
P/B 35.67 2.89 98%
P/E 134.7 17.2 95%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 4.0 1.1 84%
Ratios ETON Industry
Median
Percentile
(All Stocks)
Gross Margin 60.5% 67.5% 73%
Net Margin 12.0% (2.3%) 67%
ROA 11.7% (22.5%) 90%
ROE 36.0% (19.8%) 90%
Liabilities to Assets 59.8% 32.4% 54%
F-Score 6 3 67%

Passing Stock Screens

As of 8/14/2026, from a list of 60 stock screening strategies, ETON meetings the criteria of 1 screen: